SciSparc Ltd. (SPRC)

NASDAQ: SPRC · IEX Real-Time Price · USD
5.01 -0.58 (-10.38%)
Jan 24, 2022 4:00 PM EST - Market closed
Market Cap727.19M
Revenue (ttm)n/a
Net Income (ttm)3.49M
Shares Out145.15M
EPS (ttm)-3.42
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume13,187
Openn/a
Previous Close5.59
Day's Range4.98 - 5.54
52-Week Range4.98 - 7.08
Beta-0.10
Analystsn/a
Price Targetn/a
Earnings Daten/a

About SPRC

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. SciSparc Ltd. has an agreement with Procaps to develop and commercially manufacture SCI-110, as well as CannAmide, a palmitoylethanolamide compound in softgel capsule form. It also...

IndustryBiotechnology
Founded2004
Employees2
Stock ExchangeNASDAQ
Ticker SymbolSPRC
Full Company Profile

Financial Performance

Financial Statements

News

SciSparc Advances Its Phase IIb Clinical Trial in Patients with Tourette Syndrome with its Proprietary Drug Candidate...

TEL AVIV, Israel, Jan. 18, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the centra...

1 week ago - PRNewsWire

SciSparc Exploring Psychedelics as Possible Avenue to Expand Its IP Portfolio

TEL AVIV, Israel, Jan. 11, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the centra...

2 weeks ago - PRNewsWire

SciSparc Announces Recruitment of First Patient for its Phase IIa Clinical Trial in Alzheimer's Disease

TEL AVIV, Israel, Jan. 6, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC) (the "Company"), a clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the ce...

2 weeks ago - PRNewsWire

SciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems Disorders

TEL AVIV, Israel, Jan. 4, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central...

2 weeks ago - PRNewsWire

SciSparc Provides Updates Upon Conclusion of 2021

TEL AVIV, Israel, Dec. 29, 2021 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the centra...

3 weeks ago - PRNewsWire

SciSparc's Ordinary Shares to Commence Trading on Nasdaq Capital Market Today

TEL AVIV, Israel, Dec. 22, 2021 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC) a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central...

1 month ago - PRNewsWire